Benefit-risk assessment of interferon-b therapy for relapsing multiple sclerosis
- 1 July 2004
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 3 (4) , 289-303
Abstract
IFN-beta therapy has a central place in the management of relapsing multiple sclerosis, as demonstrated by the pivotal studies of three IFN-beta treatment regimens. However, questions remain concerning the optimal choice of preparation and dose regimen. The benefit-risk ratio for a given preparation is an important consideration in optimising treatment for an individual patient. Of the three IFN-beta preparations currently available, all have shown benefit on activity measures (relapses and active lesions apparent on magnetic resonance imaging), while benefit on progression measures (disability and total lesion burden) has been less consistent. Available data across studies suggest that dose and/or dose frequency are important determinants of efficacy, a finding supported by direct comparative data on different IFN-beta preparations. The added benefit of high-dose, high-frequency IFN-beta therapy is not achieved at the cost of compromised safety or tolerability, indicating that three-times-weekly treatment offers a superior benefit-risk ratio to once-weekly treatment. The potential advantages of IFN-beta therapy may be enhanced by regular monitoring of efficacy and safety in order to maintain patients on therapy beyond the first few months when side effects are most apparent.Keywords
This publication has 8 references indexed in Scilit:
- Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosisThe Lancet, 2003
- Interferon-beta antibodies: implications for the treatment of MSThe Lancet Neurology, 2003
- A Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2003
- Short Communication: A Comparison of the Biologic Activity of Two Recombinant IFN- β Preparations Used in the Treatment of Relapsing-Remitting Multiple SclerosisJournal of Interferon & Cytokine Research, 2002
- Neutralising antibodies to interferon beta during the treatment of multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis CNew England Journal of Medicine, 2000
- Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosisNeurology, 1998
- Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1bNeurology, 1996